WO2006096996A1 - Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition - Google Patents

Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition Download PDF

Info

Publication number
WO2006096996A1
WO2006096996A1 PCT/CA2006/000415 CA2006000415W WO2006096996A1 WO 2006096996 A1 WO2006096996 A1 WO 2006096996A1 CA 2006000415 W CA2006000415 W CA 2006000415W WO 2006096996 A1 WO2006096996 A1 WO 2006096996A1
Authority
WO
WIPO (PCT)
Prior art keywords
increasing
extract
subject
composition according
thermogenesis
Prior art date
Application number
PCT/CA2006/000415
Other languages
French (fr)
Inventor
Marvin A. Heuer
Original Assignee
Ripped Formulations Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ripped Formulations Ltd. filed Critical Ripped Formulations Ltd.
Priority to CA002600301A priority Critical patent/CA2600301A1/en
Priority to AU2006225005A priority patent/AU2006225005A1/en
Priority to EP06741359A priority patent/EP1863433A4/en
Publication of WO2006096996A1 publication Critical patent/WO2006096996A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia

Definitions

  • the present invention relates to compositions and methods for increasing a person's natural metabolic rate, increasing thermogenesis or decreasing water retention.
  • the present invention comprises a composition of a first combination that comprises green tea extract, anhydrous caffeine, and guarana powder; a second combination that comprises dandelion root extract, and juniper berry powder; and a third combination that comprises N-acetyl-L-tyrosine, and gynostemma pentaphyullum.
  • the present invention may also comprise thiamin, pyridoxine, niacin, quercetin dehydrate, cayenne pepper powder, oolong tea extract, white tea extract, theobroma cocao extract, vinpocetine, yerba mate leaf powder, parsley powder extract, picamilone, and xanthinol nicotinate.
  • the present invention provides methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject utilizing the invention.
  • the present invention provides methods of reducing body fat mass leading to weight loss and improving muscular definition in subjects.
  • the present invention provides a composition for increasing a subject's natural metabolic rate and/or decreasing water retention, thus reducing a subject's body fat mass leading to weight loss and improving visible muscular definition.
  • Certain embodiments of the present invention include diet supplements.
  • the present invention may allow a subject to burn more calories than the subject would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
  • the present invention provides compositions and methods that decrease water retention in subjects.
  • the composition and method may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
  • a composition and related methods comprise: a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, anhydrous caffeine, niacin, and yerba mate extract, and guarana extract; a second combination of one or more of dandelion root extract, juniper berry powder, parsley powder (leaf) and cayenne pepper powder; a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine.
  • the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia, and/or xanthinol nicotinate.
  • the present invention may further comprise ingredients such as, thiamin or any salts or esters thereof, niacin, xantinol nicotinate, picamilone, and pyridoxine or a salt thereof in any of its pharmaceutically acceptable forms.
  • the diet supplement may be consumed in any form.
  • the dosage form of the diet supplement may be as a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a tablet, a caplet, or as a dietary gel.
  • the dosage form of the diet supplement in accordance with these embodiments may be provided in accordance with customary processing techniques for herbal and/or diet supplements in any of the forms mentioned above.
  • a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
  • a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
  • compositions according to the present invention may be employed in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in subjects.
  • the compositions of the present invention are particularly advantageous for athletes and bodybuilders to improve muscular definition.
  • the dosage amount of the compositions according to the present invention which is administered to a subject may vary depending on the desired effect, the body weight and other characteristics of the subject.
  • the compositions according to the present invention are administered to the subject on a daily basis.
  • the compositions according to the present invention are administered to the subject three times daily.
  • the present invention also provides a method of increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject.
  • the methods of the present invention include administering a composition to a subject.
  • methods for reducing body fat mass leading to weight loss and thus improving visible muscular definition are provided.
  • the administration of compositions according to the present invention allow a person's body to burn more calories than the person's body would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
  • the methods of the present invention provide for the administration of compositions according to the present invention that decrease water retention.
  • the administration of compositions according to the present invention may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
  • compositions and related methods comprising a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, caffeine, niacin, and yerba mate extract, and guarana extract; a second combination of one more of dandelion root extract, juniper berry powder, parsley powder (leaf), cayenne pepper powder, and xanthinol nicotinate; a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine.
  • the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia extract, and/or xanthinol nicotinate.
  • compositions according to the present invention may be administered in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
  • the methods of the present invention are particularly advantageous for athletes and bodybuilders to improve visible muscular definition.
  • the methods of the present invention include a determination, and an administration, of an amount of a composition in accordance with factors such as the desired effect, the body weight and characteristics of the athlete.
  • the present invention includes methods of administering compositions according to the invention to subjects on a daily basis or three times daily.
  • the following composition is provided: green tea extract (0.4440 g), caffeine anhydrous (0.3000 g), dandelion root powder (0.2500 g), parsley powder (0.2000 g), juniper berry powder (0.2000 g), cayenne pepper powder (0.1000 g), n-acetyl-l-tyrosine (0.1000 g), quercetin dehydrate (0.1000 g), picamilone HCI (0.1000 g), gynostemma pentaphyullum leaf exact (0.0350 g), niacin (0.0330 g), oolong tea dry leaf extract (0.0100 g), white tea dry leaf extract (0.0100 g), theobroma cocao extract (0.0100 g), vinpocetine (0.0050 g), pyridoxine HCI (0.0020 g), thiamin mononitrate (0.0015 g), guarana powder (0.0010 g), yerba mate leaf powder (0.0010 g
  • the example composition may be ingested 30 to 60 minutes prior to eating a meal.
  • the example composition can also be consumed prior exercise to increase and athlete's training intensity.
  • the example composition may be ingested 30 to 60 minutes prior to eating a meal.
  • the example composition can also be consumed prior exercise to increase and athlete's training intensity.

Abstract

Compositions and methods for administering the same to humans are provided for the promotion of increasing a person's natural metabolic rate, increasing thermogenesis, increasing training intensity, increasing muscular definition, and/or decreasing water retention. Said compositions comprise, green tea extract, anhydrous caffeine, theobroma cocao extract, oolong tea extract, white tea extract, guarana, yerba mate powder, dandelion root extract, juniper berry powder, parsley powder garcinia cambogia extract, cayenne pepper powder extract, n-acetyl-l-tyrosine, quercetin dehydrate, gynostemma pentaphyullum extract, vinpocetine and optionally thiamin, pyridoxine, picamilone, xanthinol nicotinate, garcinia cambogia extract and niacin.

Description

Compositions and Methods for Increasing Metabolism, Thermogenesis and/or
Muscular Definition
Field of the Invention
The present invention relates to compositions and methods for increasing a person's natural metabolic rate, increasing thermogenesis or decreasing water retention.
Summary of the Invention
In one aspect, the present invention comprises a composition of a first combination that comprises green tea extract, anhydrous caffeine, and guarana powder; a second combination that comprises dandelion root extract, and juniper berry powder; and a third combination that comprises N-acetyl-L-tyrosine, and gynostemma pentaphyullum. Additionally, the present invention may also comprise thiamin, pyridoxine, niacin, quercetin dehydrate, cayenne pepper powder, oolong tea extract, white tea extract, theobroma cocao extract, vinpocetine, yerba mate leaf powder, parsley powder extract, picamilone, and xanthinol nicotinate. In another aspect, the present invention provides methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject utilizing the invention. In another aspect, the present invention provides methods of reducing body fat mass leading to weight loss and improving muscular definition in subjects.
Detailed Description of the Invention
The present invention, according to one embodiment, provides a composition for increasing a subject's natural metabolic rate and/or decreasing water retention, thus reducing a subject's body fat mass leading to weight loss and improving visible muscular definition. Certain embodiments of the present invention include diet supplements. According to other embodiments of the present invention, there is provided a composition that reduces body fat mass leading to weight loss, thus improving muscular definition. In one embodiment the present invention may allow a subject to burn more calories than the subject would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
In another embodiment the present invention provides compositions and methods that decrease water retention in subjects. For example, the composition and method may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
In certain embodiments of the present invention, a composition and related methods comprise: a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, anhydrous caffeine, niacin, and yerba mate extract, and guarana extract; a second combination of one or more of dandelion root extract, juniper berry powder, parsley powder (leaf) and cayenne pepper powder; a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine. Additionally, the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia, and/or xanthinol nicotinate. In another embodiment, the present invention may further comprise ingredients such as, thiamin or any salts or esters thereof, niacin, xantinol nicotinate, picamilone, and pyridoxine or a salt thereof in any of its pharmaceutically acceptable forms.
Compounds according to the present invention have been shown to have thermogenic effects. Catechin epigallocatechin-3-gallate (EGCG), a component of green tea, has been shown to possess the ability to give to rise to thermogenic effects. In one study (Berube-Parent S, Pelletier C, Dore J, Tremblay A. (2005) "Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin- 3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men." Br J Nutr. Sep;94(3):432-6.) the energy expenditure and fat oxidation over a 24-hour time period employing components of the present invention was observed. Fourteen subjects took part in a randomized, placebo-controlled, double blind, crossover study. Each subject was tested 5 times in a metabolic chamber to measure 24-hour energy expenditure, substrate oxidation and blood pressure. During each stay, the subjects ingested a placebo or capsules containing components of the present invention 30 minutes before standardized meals. It was found that 24-hour energy expenditure increased significantly by about 750 kJ within all the treatment groups compared to placebo. This study found an increase in the 24-hour energy expenditure in the treatment groups. The resultant increase in energy expenditure via treatment with components comprising the present invention leads to an increase in the natural metabolic rate, the burning of calories, and an increase in thermogenesis.
Where the composition is in the nature of a diet supplement, the diet supplement may be consumed in any form. For instance, the dosage form of the diet supplement may be as a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a tablet, a caplet, or as a dietary gel.
Furthermore, the dosage form of the diet supplement in accordance with these embodiments may be provided in accordance with customary processing techniques for herbal and/or diet supplements in any of the forms mentioned above.
In one embodiment of the present invention, which is set forth in greater detail in Example 1 below, a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
In a second embodiment of the present invention, which is set forth in greater detail in Example 2 below, a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
The compositions according to the present invention may be employed in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in subjects. The compositions of the present invention are particularly advantageous for athletes and bodybuilders to improve muscular definition. The dosage amount of the compositions according to the present invention which is administered to a subject may vary depending on the desired effect, the body weight and other characteristics of the subject. For example, in various embodiments, the compositions according to the present invention are administered to the subject on a daily basis. In another embodiment the compositions according to the present invention are administered to the subject three times daily.
The present invention also provides a method of increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject. In one embodiment, the methods of the present invention include administering a composition to a subject. According to another embodiment of the present invention, methods for reducing body fat mass leading to weight loss and thus improving visible muscular definition are provided. In one embodiment , the administration of compositions according to the present invention allow a person's body to burn more calories than the person's body would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
In example embodiments set forth below, the methods of the present invention provide for the administration of compositions according to the present invention that decrease water retention. For example, the administration of compositions according to the present invention may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
In embodiments described in the examples below, compositions and related methods comprising a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, caffeine, niacin, and yerba mate extract, and guarana extract; a second combination of one more of dandelion root extract, juniper berry powder, parsley powder (leaf), cayenne pepper powder, and xanthinol nicotinate; a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine. Additionally, the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia extract, and/or xanthinol nicotinate.
The compositions according to the present invention may be administered in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention. The methods of the present invention are particularly advantageous for athletes and bodybuilders to improve visible muscular definition. In certain embodiments, the methods of the present invention include a determination, and an administration, of an amount of a composition in accordance with factors such as the desired effect, the body weight and characteristics of the athlete. For example, in certain embodiments, the present invention includes methods of administering compositions according to the invention to subjects on a daily basis or three times daily.
Although the following example illustrates the practice of the present invention in example embodiments, the examples should not be construed as limiting the scope of the invention. Other embodiments will be apparent to one skilled in the art from consideration of the specification and example.
Example 1
As a first example, the following composition is provided: green tea extract (0.4440 g), caffeine anhydrous (0.3000 g), dandelion root powder (0.2500 g), parsley powder (0.2000 g), juniper berry powder (0.2000 g), cayenne pepper powder (0.1000 g), n-acetyl-l-tyrosine (0.1000 g), quercetin dehydrate (0.1000 g), picamilone HCI (0.1000 g), gynostemma pentaphyullum leaf exact (0.0350 g), niacin (0.0330 g), oolong tea dry leaf extract (0.0100 g), white tea dry leaf extract (0.0100 g), theobroma cocao extract (0.0100 g), vinpocetine (0.0050 g), pyridoxine HCI (0.0020 g), thiamin mononitrate (0.0015 g), guarana powder (0.0010 g), yerba mate leaf powder (0.0010 g), gelatin, titanium dioxide, microcrystalline cellulose (0.0660 g), magnesium stearate (0.0330 g), and silica (0.0165 g).
The example composition may be ingested 30 to 60 minutes prior to eating a meal. The example composition can also be consumed prior exercise to increase and athlete's training intensity.
Example 2
As a second example, the following composition is provided: green tea extract
(0.440 g), caffeine anhydrous (0.3000 g), dandelion root powder (0.2500 g), parsley powder (0.2000 g), juniper berry powder (0.200), cayenne pepper powder (0.100 g), n- acetyl-l-tyrosine (0.1000 g), quercetin dehydrate (0.1000 g), xanthinol nicotinate (0.1000 g), gynostemma pentaphyullum leaf exact (0.0350 g), niacin (0.0330 g), oolong tea dry leaf extract (0.0100 g), white tea dry leaf extract (0.0100 g), theobroma cocao extract (0.0100 g), vinpocetine (0.0050 g), pyridoxine HCI (0.0020 g), thiamin mononitrate (0.0015 g), guarana powder (0.0010 g), yerba mate leaf powder (0.0010), gelatin, titanium dioxide, microcrystalline cellulose (0.0660), magnesium stearate (0.0330 g), and silica (0.0165 g).
The example composition may be ingested 30 to 60 minutes prior to eating a meal. The example composition can also be consumed prior exercise to increase and athlete's training intensity.

Claims

Claims:What is claimed:
1. A composition comprising at least two of: a first combination that comprises Green Tea Extract, Anhydrous Caffeine, and Guarana Extract; a second combination that comprises Dandelion Root Extract, and Juniper Berry Powder; and a third combination that comprises N-Acetyl-L-Tyrosine, and Gynostemma Pentaphyullum.
2. A composition according to claim 1 furthering comprising Thiamin.
3. A composition according to claim 1 furthering comprising Pyridoxine.
4. A composition according to claim 1 furthering comprising Niacin.
5. A composition according to claim 1 further comprising Picamilone.
6. A composition according to claimi further comprising Xantinol Nicotinate.
7. A composition according to claim 1 further comprising Garcinia Cambogia extract.
8. A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 1.
9. A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 2.
10. A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 3.
11. A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 4.
12. A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 5.
13. A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 6.
14. A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 7.
PCT/CA2006/000415 2005-03-18 2006-03-20 Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition WO2006096996A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002600301A CA2600301A1 (en) 2005-03-18 2006-03-20 Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
AU2006225005A AU2006225005A1 (en) 2005-03-18 2006-03-20 Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
EP06741359A EP1863433A4 (en) 2005-03-18 2006-03-20 Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66339605P 2005-03-18 2005-03-18
US60/663,396 2005-03-18

Publications (1)

Publication Number Publication Date
WO2006096996A1 true WO2006096996A1 (en) 2006-09-21

Family

ID=36991257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/000415 WO2006096996A1 (en) 2005-03-18 2006-03-20 Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition

Country Status (5)

Country Link
EP (1) EP1863433A4 (en)
AU (1) AU2006225005A1 (en)
CA (1) CA2600301A1 (en)
WO (1) WO2006096996A1 (en)
ZA (1) ZA200708361B (en)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904070A1 (en) * 2005-07-07 2008-04-02 H3 Formulations Ltd. Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
FR2938735A1 (en) * 2008-11-21 2010-05-28 Holymark Dieting composition, useful for reducing weight and as dietary supplement, preferably for sportsman comprises epigallocatechin gallate, capsaicin, caffeine, tyrosine and extract of white bean (Phaseolus vulgaris)
WO2010142750A1 (en) * 2009-06-11 2010-12-16 Dsm Ip Assets B.V. Niacin and/or trigonelline as a muscle stimulant
ES2386858A1 (en) * 2011-02-07 2012-09-03 Eduardo Antonio Gómez De Diego Natural slimming composition. (Machine-translation by Google Translate, not legally binding)
WO2013168019A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neuropathic pain
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9102649B1 (en) 2014-09-29 2015-08-11 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9174931B2 (en) 2013-06-04 2015-11-03 Cellix Bio Private Limited Compositions for the treatment of diabetes and pre-diabetes
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9580383B2 (en) 2012-05-23 2017-02-28 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
US9642915B2 (en) 2012-05-07 2017-05-09 Cellix Bio Private Limited Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9725404B2 (en) 2014-10-27 2017-08-08 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
US9771355B2 (en) 2014-09-26 2017-09-26 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US10227301B2 (en) 2015-01-06 2019-03-12 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
WO2019178689A1 (en) * 2018-03-20 2019-09-26 Exerkine Corporation Weight management composition
US20210077517A1 (en) * 2008-06-13 2021-03-18 International IP Holdings Edible Energy Composition
US20210121469A1 (en) * 2008-06-13 2021-04-29 International Ip Holdings Llc Edible Energy Composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277396B1 (en) * 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
US20050008690A1 (en) * 2002-04-10 2005-01-13 Miller Fred H. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005368A1 (en) * 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277396B1 (en) * 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
US20050008690A1 (en) * 2002-04-10 2005-01-13 Miller Fred H. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1863433A4 *

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904070A1 (en) * 2005-07-07 2008-04-02 H3 Formulations Ltd. Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
EP1904070A4 (en) * 2005-07-07 2009-09-02 H3 Formulations Ltd Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
US20210121469A1 (en) * 2008-06-13 2021-04-29 International Ip Holdings Llc Edible Energy Composition
US20210077517A1 (en) * 2008-06-13 2021-03-18 International IP Holdings Edible Energy Composition
FR2938735A1 (en) * 2008-11-21 2010-05-28 Holymark Dieting composition, useful for reducing weight and as dietary supplement, preferably for sportsman comprises epigallocatechin gallate, capsaicin, caffeine, tyrosine and extract of white bean (Phaseolus vulgaris)
WO2010142750A1 (en) * 2009-06-11 2010-12-16 Dsm Ip Assets B.V. Niacin and/or trigonelline as a muscle stimulant
US8323707B2 (en) 2009-06-11 2012-12-04 Dsm Ip Assets B.V. Trigonelline as a muscle stimulant
US8772230B2 (en) 2009-06-11 2014-07-08 Dsm Ip Assets B.V. Niacin and/or trigonelline as a muscle stimulant
US9241938B2 (en) 2009-06-11 2016-01-26 Dsm Ip Assets B.V. Trigonelline as a muscle stimulant
ES2386858A1 (en) * 2011-02-07 2012-09-03 Eduardo Antonio Gómez De Diego Natural slimming composition. (Machine-translation by Google Translate, not legally binding)
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9642915B2 (en) 2012-05-07 2017-05-09 Cellix Bio Private Limited Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013168019A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neuropathic pain
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9580383B2 (en) 2012-05-23 2017-02-28 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9403793B2 (en) 2012-07-03 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9174931B2 (en) 2013-06-04 2015-11-03 Cellix Bio Private Limited Compositions for the treatment of diabetes and pre-diabetes
US9840472B2 (en) 2013-12-07 2017-12-12 Cellix Bio Private Limited Compositions and methods for the treatment of mucositis
US9771355B2 (en) 2014-09-26 2017-09-26 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
US9102649B1 (en) 2014-09-29 2015-08-11 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
US9988340B2 (en) 2014-09-29 2018-06-05 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9725404B2 (en) 2014-10-27 2017-08-08 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
US10227301B2 (en) 2015-01-06 2019-03-12 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
US10343994B2 (en) 2015-01-06 2019-07-09 Mahesh Kandula Compositions and methods for the treatment of inflammation and pain
WO2019178689A1 (en) * 2018-03-20 2019-09-26 Exerkine Corporation Weight management composition
CN112118855A (en) * 2018-03-20 2020-12-22 爱瑟金股份有限公司 Weight management composition
US11167001B2 (en) 2018-03-20 2021-11-09 Exerkine Corporation Weight management composition

Also Published As

Publication number Publication date
EP1863433A4 (en) 2009-09-09
ZA200708361B (en) 2008-10-29
CA2600301A1 (en) 2006-09-21
AU2006225005A1 (en) 2006-09-21
EP1863433A1 (en) 2007-12-12

Similar Documents

Publication Publication Date Title
WO2006096996A1 (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
US20060210653A1 (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
US7989009B2 (en) Composition and method for promoting weight loss
US20050249827A1 (en) Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite
AU2019200802B2 (en) Synergistic dietary supplement compositions for enhancing physical performance
US9220741B2 (en) Weight loss formulation
US7943183B2 (en) Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
AU2007222860A1 (en) Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis
Cherniack Potential applications for alternative medicine to treat obesity in an aging population
WO2018112475A1 (en) Energy compositions and methods
US20040097429A1 (en) Method for the reduction of the mammalian appetite
US20080279967A1 (en) Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid
US20130280367A1 (en) Method and Composition for Increasing Energy and Focus
CA2751218C (en) Weight loss formulation
CA2446254C (en) New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits
Shane-McWhorter Complementary and alternative medicine (CAM) supplement use in people with diabetes: a clinician's guide
US20050276870A1 (en) Food supplement formulation
WO2011159850A2 (en) Lip cosmetic formulations
PT103650B (en) COMPOSITIONS OF VEGETABLE EXTRACTS
KR20050038766A (en) New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits
CA2588491A1 (en) Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid profile

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2600301

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006225005

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006741359

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4627/CHENP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

ENP Entry into the national phase

Ref document number: 2006225005

Country of ref document: AU

Date of ref document: 20060320

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006225005

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006741359

Country of ref document: EP